<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; National</title>
	<atom:link href="http://www.tapanray.in/tag/national/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>A Rare Strategic Acrobatic Feat in Covid Time</title>
		<link>http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-rare-strategic-acrobatic-feat-in-covid-time</link>
		<comments>http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/#comments</comments>
		<pubDate>Mon, 21 Dec 2020 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[acrobatic]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Alexion]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[comorbidity]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[feat]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[infected patients]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[misdiagnosis]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[National Policy on rare diseases 2020]]></category>
		<category><![CDATA[new Coronavirus]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[rare diseases]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[time]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10376</guid>
		<description><![CDATA[‘Keep nose to the grindstone while lifting eyes to the hills.’ Quite a while ago, all-time global management guru – Peter Drucker used this essential acrobatic feat as an example, for the business strategists. This illustration signifies the criticality of harmonizing decisions &#8230; <a href="http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Enhancing Pharma Brand Experience In The New Normal</title>
		<link>http://www.tapanray.in/enhancing-pharma-brand-experience-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=enhancing-pharma-brand-experience-in-the-new-normal</link>
		<comments>http://www.tapanray.in/enhancing-pharma-brand-experience-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 22 Jun 2020 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[approaches]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[end-to-end]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[journey]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[mapping]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[restart]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[touchpoint]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[unlock down]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10137</guid>
		<description><![CDATA[In these days of unprecedented and all-pervasive disruptions &#8211; almost in every facet of life &#8211; caused by an unknown virus, scramble to find an effective solution for saving lives and livelihoods, still continue. The discomfiture seems to be omnipresent &#8230; <a href="http://www.tapanray.in/enhancing-pharma-brand-experience-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/enhancing-pharma-brand-experience-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Multifaceted Coronavirus Narrative Raises Multiple Questions</title>
		<link>http://www.tapanray.in/multifaceted-coronavirus-narrative-raises-multiple-questions/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=multifaceted-coronavirus-narrative-raises-multiple-questions</link>
		<comments>http://www.tapanray.in/multifaceted-coronavirus-narrative-raises-multiple-questions/#comments</comments>
		<pubDate>Mon, 06 Apr 2020 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[21 day]]></category>
		<category><![CDATA[attack]]></category>
		<category><![CDATA[battle gear]]></category>
		<category><![CDATA[cacophony]]></category>
		<category><![CDATA[CJI]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Covid19]]></category>
		<category><![CDATA[Deadly]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[fallout]]></category>
		<category><![CDATA[Gear]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[invisible]]></category>
		<category><![CDATA[laborers]]></category>
		<category><![CDATA[like]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[microbe]]></category>
		<category><![CDATA[migrant]]></category>
		<category><![CDATA[Multifaceted]]></category>
		<category><![CDATA[Narrative. Raises. Multiple]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[paramedic]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[PPE]]></category>
		<category><![CDATA[protective]]></category>
		<category><![CDATA[questions]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Serbia]]></category>
		<category><![CDATA[showstoppers]]></category>
		<category><![CDATA[situation]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[testing]]></category>
		<category><![CDATA[violation]]></category>
		<category><![CDATA[W.H.O]]></category>
		<category><![CDATA[war]]></category>
		<category><![CDATA[workforce]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9960</guid>
		<description><![CDATA[Last night, amid the national lockdown, many people followed Prime Minister Modi’s video message, broadcasted on April 03 at 9 am for all, ‘to challenge the darkness of Coronavirus together &#8211; with a Diya, candle, torch or flashlight, at 9 pm for 9 &#8230; <a href="http://www.tapanray.in/multifaceted-coronavirus-narrative-raises-multiple-questions/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/multifaceted-coronavirus-narrative-raises-multiple-questions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cacophony Over Coronavirus Lockdown</title>
		<link>http://www.tapanray.in/cacophony-over-coronavirus-lockdown/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=cacophony-over-coronavirus-lockdown</link>
		<comments>http://www.tapanray.in/cacophony-over-coronavirus-lockdown/#comments</comments>
		<pubDate>Mon, 30 Mar 2020 00:00:57 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cacophony]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid19]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[equipment]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[kit]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[masks]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[options]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[PPE]]></category>
		<category><![CDATA[preparedness]]></category>
		<category><![CDATA[protective]]></category>
		<category><![CDATA[rationale]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recommendations]]></category>
		<category><![CDATA[religious]]></category>
		<category><![CDATA[sanitizer]]></category>
		<category><![CDATA[solutions]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[testing]]></category>
		<category><![CDATA[tests]]></category>
		<category><![CDATA[viruses]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9943</guid>
		<description><![CDATA[Currently, the entire India is trying hard to comply with the 21-day lockdown of the country, as communicated by Prime Minister Narendra Modi to the nation at 8 pm on March 24, 2020. The very next day,  while addressing his parliamentary &#8230; <a href="http://www.tapanray.in/cacophony-over-coronavirus-lockdown/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/cacophony-over-coronavirus-lockdown/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Access To Comprehensive Healthcare Merits Multipronged Approach</title>
		<link>http://www.tapanray.in/access-to-comprehensive-healthcare-merits-multipronged-approach/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=access-to-comprehensive-healthcare-merits-multipronged-approach</link>
		<comments>http://www.tapanray.in/access-to-comprehensive-healthcare-merits-multipronged-approach/#comments</comments>
		<pubDate>Mon, 10 Dec 2018 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2018]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[band-aid]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[comprehensive]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Gordian]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[knot]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mental]]></category>
		<category><![CDATA[multi-pronged]]></category>
		<category><![CDATA[multifactorial]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NHP]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9296</guid>
		<description><![CDATA[Since the turn of the new millennium, several high profile and flagship health schemes are being announced in India by the Union successive governments. Some of the important ones will include the National Health Mission, Rashtriya Swasthya Bima Yojana (RSBY) - a Health &#8230; <a href="http://www.tapanray.in/access-to-comprehensive-healthcare-merits-multipronged-approach/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/access-to-comprehensive-healthcare-merits-multipronged-approach/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Policy Execution Gap Limits Access To Affordable Medicines?</title>
		<link>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-policy-execution-gap-limits-access-to-affordable-medicines</link>
		<comments>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/#comments</comments>
		<pubDate>Mon, 15 Oct 2018 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2001]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[declaration]]></category>
		<category><![CDATA[Doha]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[execution]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[payers]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[VBP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9215</guid>
		<description><![CDATA[“The cost of new drugs is putting increasing pressure on people in both rich and poor countries”- was eloquently expressed in an article, titled “Why do new medicines cost so much, and what can we do about it?”. This was &#8230; <a href="http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Will AB-NHPM Mitigate Indian Healthcare Crisis?</title>
		<link>http://www.tapanray.in/will-ab-nhpm-mitigate-indian-healthcare-crisis/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=will-ab-nhpm-mitigate-indian-healthcare-crisis</link>
		<comments>http://www.tapanray.in/will-ab-nhpm-mitigate-indian-healthcare-crisis/#comments</comments>
		<pubDate>Mon, 18 Jun 2018 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AB]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[Ayusman]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inpatient]]></category>
		<category><![CDATA[mission]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NHFS]]></category>
		<category><![CDATA[NHM]]></category>
		<category><![CDATA[NHPM]]></category>
		<category><![CDATA[NHRM]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[OOPE]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[outpatient]]></category>
		<category><![CDATA[primary]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RSBY]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[secondary]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tertiary]]></category>
		<category><![CDATA[transportation]]></category>
		<category><![CDATA[urban]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9039</guid>
		<description><![CDATA[Since long, hypes have created on several healthcare schemes in India, by the successive Governments of different political dispensation. These attracted mostly positive vibes at the time of announcements. Nevertheless, as we move on, a vast majority of Indians continues &#8230; <a href="http://www.tapanray.in/will-ab-nhpm-mitigate-indian-healthcare-crisis/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/will-ab-nhpm-mitigate-indian-healthcare-crisis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why MNC Pharma Still Moans Over Indian IP Ecosystem?</title>
		<link>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-mnc-pharma-still-moans-over-indian-ip-ecosystem</link>
		<comments>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/#comments</comments>
		<pubDate>Mon, 14 May 2018 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2018]]></category>
		<category><![CDATA[3.d]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[Chamber]]></category>
		<category><![CDATA[Cheaper]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[Form 27]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Moon]]></category>
		<category><![CDATA[multi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[TADF]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USTR]]></category>
		<category><![CDATA[working]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9004</guid>
		<description><![CDATA[Improving patient access to expensive drugs, paving the way for entry of their cheaper generic equivalents, post patent expiry, and avoiding evergreening, is assuming priority a priority focus area in many countries. The United States is no exception, in this &#8230; <a href="http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An Interesting Link: Productivity At Work And Employee Fitness (Part 2)</title>
		<link>http://www.tapanray.in/an-interesting-link-productivity-at-work-and-employee-fitness-part-2/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-interesting-link-productivity-at-work-and-employee-fitness-part-2</link>
		<comments>http://www.tapanray.in/an-interesting-link-productivity-at-work-and-employee-fitness-part-2/#comments</comments>
		<pubDate>Mon, 23 Apr 2018 00:00:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[changes]]></category>
		<category><![CDATA[fitness]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[mental]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[physical]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Survey]]></category>
		<category><![CDATA[Taboo]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[VUCA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8923</guid>
		<description><![CDATA[Part 2: Mental Fitness As I wrote in my previous article, the complex multi-factorial work-life challenges in today’s Volatile, Uncertain, Complex and Ambiguous (VUCA)) world are virtually unprecedented. Interestingly, a sizeable part of such challenge is related to a wide &#8230; <a href="http://www.tapanray.in/an-interesting-link-productivity-at-work-and-employee-fitness-part-2/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-interesting-link-productivity-at-work-and-employee-fitness-part-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Pricing Pressure to Escalate Further?</title>
		<link>http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-pricing-pressure-to-escalate-further</link>
		<comments>http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/#comments</comments>
		<pubDate>Mon, 12 Feb 2018 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2018]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[Central Medical]]></category>
		<category><![CDATA[CMSS]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[escalate]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[HPS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Niti Aayog]]></category>
		<category><![CDATA[OOPE]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Progressive India” report]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[“Healthy States]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8849</guid>
		<description><![CDATA[On February 09, 2018, NITI Aayog released its “Healthy States, Progressive India” Report. The study ranked the States based on ‘health index’. Kerala, Punjab and Tamil Nadu featured as top three in terms of overall performance in 2015-16. However, the interstate variation &#8230; <a href="http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
